Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Breast cancer is the most common cancer in women worldwide. Its molecular classification, based on hormone receptors (estrogen and progesterone), HER2 and Ki-67, defines subtypes with different prognoses and treatments. In Colombia, there is limited information that integrates the clinical, treatment, sociodemographic and contextual characteristics of each subtype, and limited data on the direct medical costs of breast cancer care. This retrospective cohort study will review the medical records of women 18 years or older with biopsy-confirmed breast cancer and a documented molecular subtype who were treated at Fundación Santa Fe de Bogotá (Bogotá, Colombia) between January 1, 2014 and December 31, 2024. It will describe each molecular subtype (luminal A, luminal B HER2-negative, luminal B HER2-positive, HER2-enriched, triple-negative and HER2-low) and evaluate the association of clinical, molecular and treatment characteristics with overall survival, progression-free survival, recurrence, treatment response and grade 3-4 adverse events. It will also explore the impact of the COVID-19 pandemic and health insurance regimen on outcomes, and estimate direct medical costs of breast cancer care by clinical stage and phase of care. The investigators will not assign or modify any treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobiety powyżej 18 lat z potwierdzonym rakiem piersi.
- •Pacjentki leczone w szpitalu Fundación Santa Fe de Bogotá od 2014 do 2024 roku.
- •Posiadanie informacji o podtypie molekularnym guza.
✗ Disqualifies
- •Przerzuty raka z innego miejsca w ciele do piersi.
- •Zmiany o niepewnym charakterze lub raki in situ (niewinny rodzaj raka).
- •Niekompletne dane o podtypie, leczeniu lub wynikach.
- •Pacjentki leczone poza tym szpitalem bez możliwości sprawdzenia wyników.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Hospital Universitario Fundación Santa Fe de Bogotá
Bogotá, Colombia
Trial contact
Erick Andrés Cantor Rizo, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.